ADMA Biologics Q3 revenue rises on strong ASCENIV sales

Overview

• U.S. biopharmaceutical firm's Q3 2026 revenue up 5% yr/yr, driven by ASCENIV sales

• Adjusted Basic EPS for Q3 2026 rose 44% yr/yr

• Company repurchased 2.7 mln shares in Q3 under buyback program

Outlook

• ADMA Biologics sees FY2026 revenue of at least $530 mln

• Company expects FY2026 adjusted net income of at least $180 mln

• Company raises FY2026 adjusted EBITDA outlook to at least $275 mln

Result Drivers

• ASCENIV DEMAND - Co said expanding physician adoption, new patient starts and growing end-user utilization drove ASCENIV revenue growth

• MARGIN EXPANSION - Co attributed gross margin expansion to favorable ASCENIV mix and yield-enhanced manufacturing

• BIVIGAM STABILIZATION - Co said underlying BIVIGAM utilization showed signs of stabilization despite competitive pressures

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for ADMA Biologics, Inc. is $17.50, about 57.5% above its November 3 closing price of $11.11

• The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 9 three months ago

Reuters Recommended Reads

• Nov 3 - Amgen Q3 revenue beats expectations on higher volumes

• Nov 3 - Pfizer Q3 revenue beats estimates on new launches; raises guidance

• Nov 2 - Neurocrine Biosciences Q3 revenue jumps 41% on strong INGREZZA, CRENESSITY, VYKAT XR demand

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)